Download PDF
CC BY-NC-ND 4.0 · Joints 2017; 05(02): 079-084
DOI: 10.1055/s-0037-1603677
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Early Efficacy of Intra-Articular HYADD® 4 (Hymovis®) Injections for Symptomatic Knee Osteoarthritis

Ferdinando Priano
1   Centro Ortopedico “Policlinico di Monza,” Ospedale S.M. Misericordia, Albenga, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
28 July 2017 (online)

   Permissions and Reprints

Abstract

Purpose The aim of the study was to evaluate the clinical effects of HYADD® 4, an hydrogel based on a hyaluronic acid derivative, in patients with symptomatic knee osteoarthritis, on symptoms, and joint function.

Methods This retrospective study of patients with Kellgren–Lawrence grade II to IV knee osteoarthritis (American College of Rheumatology criteria) enrolled patients who had received two infiltrations of HYADD® 4, (24 mg/3 mL) 1 week apart, and evaluated: pain at rest, pain with movement, change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score; change in nonsteroidal anti-inflammatory drugs (NSAIDs)/acetaminophen use; satisfaction with therapy; tolerability. Study duration was 6 months for all predefined endpoints, with a 6-month extension for pain symptoms only.

Results After 6 months, all predefined endpoints were evaluable in 698 of 937 enrolled patients (74.5%). Mean WOMAC scores were reduced by 56.3% from baseline (p < 0.05). NSAIDs/acetaminophen use ≥2 times/week (48.8% of patients at baseline) was substantially reduced after 1 month and was 19.6% after 6 months. After 6 months, 85.6% of patients were satisfied about efficacy. There were no significant adverse effects. The effect on resting pain was rapid, strong, and lasting: reduction from baseline was 45.1% at 1 month (p < 0.05), 56.8% at 6 months (p < 0.05), and 53.6% at 12 months (p < 0.05). Pain on moving was reduced by 47.4% after 6 months (p < 0.05) and 46.0% after 12 months (p < 0.05), results at 6 and 12 months were similar.

Conclusion HYADD® 4 is a new-generation hyaluronic acid with distinctive viscoelastic and rheological properties. In patients with mild-to-severe knee OA (Kellgren–Lawrence grades II–IV), two consecutive infiltrations 1 week apart reduced WOMAC scores and NSAIDs/acetaminophen consumption for at least 6 months. In a subpopulation (n = 106), efficacy on pain lasted approximately 12 months. Adverse events were reported in 11.2% of patients; the most frequent were arthralgias. No cases of allergic reactions or systemic effects were recorded.

Level of Evidence Level IV, retrospective case series.

Keywords

hyaluronic acid - osteoarthritis - knee - viscosupplementation - Hymovis® - viscoelastic
 

  • References

  • 1 Cross M, Smith E, Hoy D. , et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014; 73 (07) 1323-1330
    CrossrefPubMedGoogle Scholar
  • 2 Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med 2010; 26 (03) 355-369
    CrossrefPubMedGoogle Scholar
  • 3 Barbour KE, Lui LY, Nevitt MC. , et al; Study of Osteoporotic Fractures Research Group. Hip osteoarthritis and the risk of all-cause and disease-specific mortality in older women: a population-based cohort study. Arthritis Rheumatol 2015; 67 (07) 1798-1805
    CrossrefPubMedGoogle Scholar
  • 4 Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ 2011; 342: d1165
    CrossrefPubMedGoogle Scholar
  • 5 Veronese N, Cereda E, Maggi S. , et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with meta-analysis. Semin Arthritis Rheum 2016; 46 (02) 160-167
    CrossrefPubMedGoogle Scholar
  • 6 Felson DT, Zhang Y, Hannan MT. , et al. Risk factors for incident radiographic knee osteoarthritis in the elderly: the Framingham Study. Arthritis Rheum 1997; 40 (04) 728-733
    CrossrefPubMedGoogle Scholar
  • 7 Muraki S, Akune T, Oka H. , et al. Incidence and risk factors for radiographic knee osteoarthritis and knee pain in Japanese men and women: a longitudinal population-based cohort study. Arthritis Rheum 2012; 64 (05) 1447-1456
    PubMedGoogle Scholar
  • 8 Kujala UM, Kettunen J, Paananen H. , et al. Knee osteoarthritis in former runners, soccer players, weight lifters, and shooters. Arthritis Rheum 1995; 38 (04) 539-546
    CrossrefPubMedGoogle Scholar
  • 9 Louboutin H, Debarge R, Richou J. , et al. Osteoarthritis in patients with anterior cruciate ligament rupture: a review of risk factors. Knee 2009; 16 (04) 239-244
    CrossrefPubMedGoogle Scholar
  • 10 Philbin EF, Ries MD, Groff GD, Sheesley KA, French TS, Pearson TA. Osteoarthritis as a determinant of an adverse coronary heart disease risk profile. J Cardiovasc Risk 1996; 3 (06) 529-533
    PubMedGoogle Scholar
  • 11 Sowers MR, Karvonen-Gutierrez CA. The evolving role of obesity in knee osteoarthritis. Curr Opin Rheumatol 2010; 22 (05) 533-537
    CrossrefPubMedGoogle Scholar
  • 12 Widhalm HK, Marlovits S, Welsch GH. , et al. Obesity-related juvenile form of cartilage lesions: a new affliction in the knees of morbidly obese children and adolescents. Eur Radiol 2012; 22 (03) 672-681
    CrossrefPubMedGoogle Scholar
  • 13 Anandacoomarasamy A, March L. Current evidence for osteoarthritis treatments. Ther Adv Musculoskelet Dis 2010; 2 (01) 17-28
    CrossrefPubMedGoogle Scholar
  • 14 Zhang W, Moskowitz RW, Nuki G. , et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16 (02) 137-162
    CrossrefPubMedGoogle Scholar
  • 15 Sofat N, Beith I, Anilkumar PG, Mitchell P. Recent clinical evidence for the treatment of osteoarthritis: what we have learned. Rev Recent Clin Trials 2011; 6 (02) 114-126
    CrossrefPubMedGoogle Scholar
  • 16 Altman RD, Akermark C, Beaulieu AD, Schnitzer T. ; Durolane International Study Group. Efficacy and safety of a single intra-articular injection of non-animal stabilized hyaluronic acid (NASHA) in patients with osteoarthritis of the knee. Osteoarthritis Cartilage 2004; 12 (08) 642-649
    CrossrefPubMedGoogle Scholar
  • 17 Piscitelli P, Iolascon G, Di Tanna G. , et al. Socioeconomic burden of total joint arthroplasty for symptomatic hip and knee osteoarthritis in the Italian population: a 5-year analysis based on hospitalization records. Arthritis Care Res (Hoboken) 2012; 64 (09) 1320-1327
    CrossrefPubMedGoogle Scholar
  • 18 Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 2003; 5 (02) 54-67
    PubMedGoogle Scholar
  • 19 Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent?. Semin Arthritis Rheum 2002; 32 (01) 10-37
    CrossrefPubMedGoogle Scholar
  • 20 Brown GA. AAOS clinical practice guideline: treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J Am Acad Orthop Surg 2013; 21 (09) 577-579
    CrossrefPubMedGoogle Scholar
  • 21 Nelson AE, Allen KD, Golightly YM, Goode AP, Jordan JM. A systematic review of recommendations and guidelines for the management of osteoarthritis: The chronic osteoarthritis management initiative of the U.S. bone and joint initiative. Semin Arthritis Rheum 2014; 43 (06) 701-712
    CrossrefPubMedGoogle Scholar
  • 22 Fernandes L, Hagen KB, Bijlsma JW. , et al; European League Against Rheumatism (EULAR). EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis 2013; 72 (07) 1125-1135
    CrossrefPubMedGoogle Scholar
  • 23 Henrotin Y, Raman R, Richette P. , et al. Consensus statement on viscosupplementation with hyaluronic acid for the management of osteoarthritis. Semin Arthritis Rheum 2015; 45 (02) 140-149
    CrossrefPubMedGoogle Scholar
  • 24 Migliore A, Bizzi E, Herrero-Beaumont J, Petrella RJ, Raman R, Chevalier X. The discrepancy between recommendations and clinical practice for viscosupplementation in osteoarthritis: mind the gap!. Eur Rev Med Pharmacol Sci 2015; 19 (07) 1124-1129
    PubMedGoogle Scholar
  • 25 Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006; (02) CD005321
    PubMedGoogle Scholar
  • 26 Finelli I, Chiessi E, Galesso D, Renier D, Paradossi G. A new viscosupplement based on partially hydrophobic hyaluronic acid: a comparative study. Biorheology 2011; 48 (05) 263-275
    PubMedGoogle Scholar
  • 27 Mainil-Varlet P, Schiavinato A, Ganster MM. Efficacy evaluation of a new hyaluronan derivative HYADD® 4-G to maintain cartilage integrity in a rabbit model of osteoarthritis. Cartilage 2013; 4 (01) 28-41
    CrossrefPubMedGoogle Scholar
  • 28 Smith MM, Cake MA, Ghosh P, Schiavinato A, Read RA, Little CB. Significant synovial pathology in a meniscectomy model of osteoarthritis: modification by intra-articular hyaluronan therapy. Rheumatology (Oxford) 2008; 47 (08) 1172-1178
    CrossrefPubMedGoogle Scholar
  • 29 Cake M, Read R, Edwards S. , et al. Changes in gait after bilateral meniscectomy in sheep: effect of two hyaluronan preparations. J Orthop Sci 2008; 13 (06) 514-523
    CrossrefPubMedGoogle Scholar
  • 30 Aletaha D, Neogi T, Silman AJ. , et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62 (09) 2569-2581
    CrossrefPubMedGoogle Scholar
  • 31 Dowsey MM, Choong PFM. The utility of outcome measures in total knee replacement surgery. Int J Rheumatol 2013; 2013: 506518
    CrossrefPubMedGoogle Scholar
  • 32 Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003; 290 (23) 3115-3121
    CrossrefPubMedGoogle Scholar
  • 33 Paoloni M, Bernetti A, Belelli A. , et al. Appropriateness of clinical and organizational criteria for intra-articular injection therapies in osteoarthritis. A Delphi method consensus initiative among experts in Italy. Ann Ist Super Sanita 2015; 51 (02) 131-138
    PubMedGoogle Scholar